Itamar Raz1, Gabriel Bitton2, Dmitry Feldman2, Tal Alon2, Andreas Pfutzner3, William V Tamborlane4. 1. Department of Medicine, Diabetes Unit, Hadassah University Hospital, Jerusalem, Israel ntv502@netvision.net.il. 2. Insuline Medical Ltd, Petach Tikva, Israel. 3. Diabetes Center and Practice, Mainz, Germany Insuline Medical Ltd, Pfützner Science & Health Institute, Mainz, Germany. 4. Department of Pediatrics, Yale School of Medicine, New Haven, CT, USA.
Abstract
BACKGROUND: Delays in the time-action profiles of premeal boluses of rapid-acting insulin analogs contribute to early postmeal hyperglycemia in patients with diabetes. We tested whether applying local heat to skin around the injection site to increase the rate of insulin absorption reduces postprandial hyperglycemia in patients with type 2 diabetes. METHODS:Fourteen patients with type 2 diabetes (4 females; age 61.6 ± 8.4 years, HbA1c 8.42 ± 1.13%; BMI 29.10 ± 5.61 kg/m(2)) on intensified insulin therapy underwent 5-hour meal tolerance tests (MTTs) with a standardized liquid meal after an overnight fast on 2 study days. Subjects injected 0.2 U/kg of insulin aspart or lispro subcutaneously into the abdominal skin on both days with and without the use of the InsuPad device. RESULTS: Following the premeal bolus injection of rapid-acting insulin analog, infusion site warming led to a rise in plasma insulin levels to peak concentrations that were significantly earlier than without skin warming (mean ± SD 52 ± 26.7 vs 80 ± 51.3 minutes, P < .005) as well as increase in plasma insulin levels during the first hour after injection (mean ± SD 63.5 ± 32.7 IU vs 48.0 ± 25.0 uU.min/ml, P = .019). As a result, the area under the curve of the postprandial glucose excursion during the first 2 hours (the primary study outcome) and the entire 5 hours after the meal were significantly reduced (P = .007 and P = .03, respectively) with skin warming around the injection site. DISCUSSION AND CONCLUSIONS: Use of the InsuPad to increase the rate of insulin absorption provides an effective means to achieve better control of postmeal glucose excursions in type 2 diabetic patients receiving premeal injections of rapid-acting insulin analogs.
RCT Entities:
BACKGROUND: Delays in the time-action profiles of premeal boluses of rapid-acting insulin analogs contribute to early postmeal hyperglycemia in patients with diabetes. We tested whether applying local heat to skin around the injection site to increase the rate of insulin absorption reduces postprandial hyperglycemia in patients with type 2 diabetes. METHODS: Fourteen patients with type 2 diabetes (4 females; age 61.6 ± 8.4 years, HbA1c 8.42 ± 1.13%; BMI 29.10 ± 5.61 kg/m(2)) on intensified insulin therapy underwent 5-hour meal tolerance tests (MTTs) with a standardized liquid meal after an overnight fast on 2 study days. Subjects injected 0.2 U/kg of insulin aspart or lispro subcutaneously into the abdominal skin on both days with and without the use of the InsuPad device. RESULTS: Following the premeal bolus injection of rapid-acting insulin analog, infusion site warming led to a rise in plasma insulin levels to peak concentrations that were significantly earlier than without skin warming (mean ± SD 52 ± 26.7 vs 80 ± 51.3 minutes, P < .005) as well as increase in plasma insulin levels during the first hour after injection (mean ± SD 63.5 ± 32.7 IU vs 48.0 ± 25.0 uU.min/ml, P = .019). As a result, the area under the curve of the postprandial glucose excursion during the first 2 hours (the primary study outcome) and the entire 5 hours after the meal were significantly reduced (P = .007 and P = .03, respectively) with skin warming around the injection site. DISCUSSION AND CONCLUSIONS: Use of the InsuPad to increase the rate of insulin absorption provides an effective means to achieve better control of postmeal glucose excursions in type 2 diabeticpatients receiving premeal injections of rapid-acting insulin analogs.
Authors: A Pfützner; N Hermanns; K Funke; T Forst; T Behnke; G Bitton; R Nagar; I Raz; T Haak Journal: Curr Med Res Opin Date: 2014-01-17 Impact factor: 2.580
Authors: J H Anderson; R L Brunelle; V A Koivisto; A Pfützner; M E Trautmann; L Vignati; R DiMarchi Journal: Diabetes Date: 1997-02 Impact factor: 9.461
Authors: Gabriel Bitton; Vital Rom; Uri Hadelsberg; Itamar Raz; Eda Cengiz; Stuart Weinzimer; William V Tamborlane Journal: J Diabetes Sci Technol Date: 2019-05-08